

Fast Facts: At 30 Sept, 2022

Ticker: GNTA
 Exchange: NASDAQ-CM
 Market Cap: ~\$91MM
 Cash Runway: ~End-2024¹
 Outstanding Shares: ~18MM

Highlights

- Overcomes key challenges of immuno-oncology
- Broad tumor applicability
- Potential for wide use in combinations
- Phase 1/2a in glioblastoma
- Solid funding & partnerships
- Research partnership with leading gene therapy institute SR-Tiget


Transformative Platform

Genenta is a clinical stage immuno-oncology company, developing a transformative platform designed to overcome the key challenges of immuno-oncology therapy today: infiltrating solid tumors, limiting toxicity and achieving a durable response.

Genenta’s proprietary platform provides one-time cell therapies to enable sustained, targeted expression of therapeutic payloads inside the tumor microenvironment.

Genenta's technology is not restricted to antigen or tumor type so has broad application potential.

Cell-Based Platform to Address Unmet Oncology Needs






Limit Expression Of Therapeutic To Tumor Microenvironment

Via proprietary transgene expression technology

Pipeline: Advancing a Cell-Based Platform Portfolio

TEMFERON™

Payload	Indication	Discovery	CTA/IND-enabling	Phase 1/2a
IFN-α	Glioblastoma Multiforme (TEM-GBM_001)			
	Solid Tumor			
	Combinations: CAR-T or ICI or TCR Solid and Hematologic Tumors			

TEMs PLATFORM

Technology	Indication	Discovery	CTA/IND-enabling	Phase 1/2a
Undisclosed payload	Solid Tumor			

Lead Product Candidate: Temferon™

Temferon utilises interferon alpha to activate an immune response. Interferon alpha is a well-known immunotherapy, limited in use due to its systemic toxicity. Our approach, designed to limit therapeutic expression to the tumor microenvironment, enables use of this powerful therapeutic.

In Genenta's ongoing Phase 1/2a trial in Glioblastoma Multiforme, an aggressive brain cancer, clinical data to date show evidence of biological activity with no dose limiting toxicities.

Management Team

Pierluigi Paracchi
Co-Founder, CEO

Luigi Naldini
Co-Founder, Exec Chair
Scientific Advisory Bd

Carlo Russo
Chief Medical Officer,
Head of Development

Richard B. Slansky
Chief Financial Officer

Upcoming Temferon Catalysts

H1 2023

Preclinical data
for combination

H2 2023

Complete enrollment for
Phase 1 of Phase 1/2a trial

H1 2024

Initiation of Phase 2 trial



Investor Contact
IR@genenta.com

Italy Dibit 1 –
San Raffaele Hospital, Via Olgettina 58, 20132 Milano

United States LaunchLabs –
Alexandria Center, 430 East 29th Street, New York, NY 10016